Pennsylvania-based Universal Health Services, Inc. (UHS) owns and operates acute care hospitals, behavioral health centers, surgical hospitals, outpatient surgery centers, and radiation oncology centers. Its market capitalization is $11.2 billion, and Universal Health operates through the acute hospital services and behavioral health services segment.
Companies worth more than $10 billion are commonly referred to as “large caps.” Universal Health fits that category, with market capitalization exceeding this threshold, reflecting the substantial size, influence and advantage of the healthcare facility industry. In addition to the services mentioned above, we also offer commercial health insurance and a variety of management services.
UHS hit a record high of $243.25 on September 24, 2024, and is now 28.7% below that peak. Over the past three months, UHS shares have fallen at just 36 bps, surpassing the 9.9% decline in Healthcare Select Sector SPDR Fund (XLV) over the same time frame.
UHS has performed slightly better than the broader health sector in the long run. UHS stocks have fallen 3.3% on a YTD basis and 8.2% over the past 52 weeks, compared to XLV's 3.9% decline in 2025 and a 10% plunge over the past year.
UHS has consistently traded its 200-day moving average from early December 2024, below the 50-day moving average from the beginning of this month.
Universal Health Services stock observed a slight DIP in the trading session after the mixed results for Q1 were announced on April 28th. The company's performance in the acute care segment remained strong, but the performance in the behavioral health segment remained poor. In the acute care segment, UHS reported an adjusted entry increase of 2.4% year-on-year and a 2.5% increase in net revenue per adjusted entry. Adjusted net revenue for the action segment per entry increased by 7.2%, while admission itself fell by 1.6%. This led to a 6.7% increase from the previous year to $4.1 billion, missing street forecasts by 1.1%.
However, the company's adjusted EPS, driven by favorable pricing and improved margins, surged 30.8% year-on-year to $4.84, surpassing the consensus estimate by 11%.
The story continues
